Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

Drug

General health

Online since 23 August 2023, updated 328 days ago

About this trial

This trial is enrolling individuals with chronic incomplete spinal cord injuries between C4 and L1 to test the safety of a drug (Rimonabant) and its potential effect on walking ability. If included, participants will either take: 1) Rimonabant 5mg per day for 90 days; or 2) a placebo drug for 90 days. Final testing of walking ability will be performed after 90 days; other safety measures will be assessed after 120 days.

Included participants

Gender

All

Age

18 - 75 years

Injury level

C4 - L1

Severity (AIS)?

AIS-C

AIS-D

Time since injury

≥ 1 year

Injury type

Traumatic

Healthy volunteers

C4-L1

Additionally, participants must

NOT have severe bone, kidney, or liver dysfunction

NOT have hypothyroidism

What’s involved

Type

Drug

Details

- participants will either take 1) Rimonabant 5mg per day for 90 days or 2) a placebo for 90 days. - Final testing of walking ability will be performed after 90 days - Final safety measures will be assessed after 120 days including e.g., adverse events, urine samples, ECG, and questionnaires.

Potential benefits

Main benefits

General health

Additional benefits

Arm/hand function

Mental health and psychosocial factors

Pain

Sensory function

Spasticity

Standing/walking/mobility

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results